| Identification | Back Directory | [Name]
N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide | [CAS]
1196119-03-5 | [Synonyms]
NCL1
N-((S)-1-(benzylcarbamoyl)-3-(3-(2-aminocyclopropyl)phenoxy)propyl)benzamide
N-[(2S)-4-[3-(2-aminocyclopropyl)phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide | [Molecular Formula]
C27H29N3O3 | [MDL Number]
MFCD22124714 | [MOL File]
1196119-03-5.mol | [Molecular Weight]
443.537 |
| Hazard Information | Back Directory | [Uses]
NCL1 is a phenylcyclopropylamine (PCPA)-based Lysine-specific demethylase 1 (LSD1) inhibitor. NCL1 selectively inhibits LSD1 in preference to LSD2, with IC50 values of 2.5 and 26 μM for LSD1 and LSD2, respectively[1]. | [IC 50]
LSD1: 2.5 ± 0.5 μM (IC50) | [References]
[1] Kakizawa T, et al. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide. Bioorg Med Chem Lett. 2016 Feb 15;26(4):1193-5. DOI:10.1016/j.bmcl.2016.01.036 |
|
|